Impel Pharmaceuticals Website, Blog & Press Pages

Impel Pharmaceuticals Website, Blog & Press Pages - aVenture

Impel Pharmaceuticals - Library

impelpharma.comCrawled Oct 15, 2026

Blog

6 pages

Assessing the comparative efficacy of INP104 for acute treatment of migraine attacks: a matching-adjusted indirect comparison Impel Pharmaceuticals/2021/06/04/assessing-the-comparative-efficacy-of-inp104-for-acute-treatment-of-migraine-attacks-a-matching-adjusted-indirect-comparison
The poster reports a matching-adjusted indirect comparison of clinical outcomes for INP104, a dihydroergotamine mesylate drug-device combination.
Cardiovascular Profile of Dihydroergotamine Mesylate (DHE) Delivered by INP104 Compared to D.H.E. 45 for Injection from the INP104-101 Clinical Trial Impel Pharmaceuticals/2019/08/05/cardiovascular-profile-of-dihydroergotamine-mesylate-dhe-delivered-by-inp104-compared-to-d-h-e-45-for-injection-from-the-inp104-101-clinical-trial
The page says DHE is effective for acute migraine and notes potential cardiovascular effects in the approved label, as well as research linking high IV DHE Cmax with increased pulmonary arterial systolic pressure.
Cardiovascular Profile of Dihydroergotamine Mesylate (DHE) Delivered by INP104 Compared to D.H.E. 45 for Injection From the INP104-101 Clinical Trial Impel Pharmaceuticals/2020/09/11/cardiovascular-profile-of-dihydroergotamine-mesylate-dhe-delivered-by-inp104-compared-to-d-h-e-45-for-injection-from-the-inp104-101-clinical-trial-2
The presentation discusses DHE as an acute migraine treatment, cardiovascular effects noted in its approved label, and clinical experience over 70 years of use.
Cardiovascular Profile of Dihydroergotamine Mesylate (DHE) Delivered by the POD Device Compared to D.H.E. 45 for Injection from the INP104-101 Clinical Trial Impel Pharmaceuticals/2019/05/23/cardiovascular-profile-of-dihydroergotamine-mesylate-dhe-delivered-by-the-pod-device-compared-to-d-h-e-45-for-injection-from-the-inp104-101-clinical-trial
The page says IV DHE is effective for acute migraine and notes potential cardiovascular effects in its approved label. It also describes Migranal as a nasal spray formulation of DHE with poor bioavailability.

Team

3 pages

Board of Directors/about-us/board-of-directors
The page describes Impel Pharmaceuticals' board of directors.
Leadership/about-us/leadership
Scientific Advisory Board/about-us/scientific-advisory-board
The page describes Impel Pharmaceuticals' scientific advisory board.

About

3 pages

About Impel/about-us
Impel Pharmaceuticals is a pharmaceutical company that developed the POD drug delivery platform for CNS diseases.
Collaborations/about-us/collaborations
The page invites inquiries about potential collaboration with Impel Pharmaceuticals or licensing its POD technology.
History/about-us/impel-history
Impel Pharmaceuticals was founded in Seattle in 2008 to research the pharmacokinetics of drugs delivered to the upper nasal cavity.

Contact

1 page

Contact/contact
The page provides instructions for reporting side effects related to an Impel product, including contact details for Impel Medical Information, healthcare providers, and the FDA.

Homepage

1 page

Homepage/
Impel Pharmaceuticals specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimer's, migraine, and other central nervous system diseases.

Privacy

1 page

Privacy Policy/privacy-policy
Impel NeuroPharma’s privacy policy describes how information provided through the website is collected, used, and disclosed.

Terms & Conditions

1 page